PATIENT Populations

DUPIXENT reduces inflammation in different patient POPULATIONS1

The approved asthma populations may include patients who exhibit other disease characteristics, such as an allergic phenotype.

DUPIXENT IS INDICATED FOR PATIENTS (12+ YEARS) WITH
MODERATE-TO-SEVERE ASTHMA WITH AN EOSINOPHILIC PHENOTYPE

Approximately 7 out of 10 asthma patients had an eosinophilic or a mixed (eosinophilic and allergic) phenotype2,a,b

DUPIXENT IS INDICATED FOR PATIENTS (12+ YEARS) WITH OCS-DEPENDENT ASTHMA, REGARDLESS OF PHENOTYPE

  • a Overlap percentages may vary depending on the number of adults vs children, ongoing therapy, and IgE and eosinophil breakpoints chosen.
  • b Based on a study of the general asthma population: Although not defined by clinical guidelines, eosinophilic phenotype was defined in this study as blood eosinophil count ≥150 cells/μL; allergic phenotype was defined in this study as allergen-specific IgE ≥0.35 IU/mL.

IgE
Eosinophils
FeNO


PATIENT PROFILES

DUPIXENT significantly reduces SEVERE exacerbations and improves lung function across THE APPROVED POPULATIONS1



Patients enrolled had elevations in multiple biomarkers, including eosinophils, IgE, and FeNO


Examples of patients with an eosinophilic phenotype or with OCS-dependent asthma

Allergic asthma patient
with elevated eosinophils
  • EOS 155 cells/µL
  • IgE 380 IU/mL
  • 2 severe exacerbations in the past year
    Compromised lung function: 70% FEV1 % predicted
  • Diagnosed with asthma as a child
    Positive skin test to a perennial aeroallergen
  • Triple therapy: ICS/LABA + LTRA
severe asthma patient
with mixed phenotype
  • EOS 320 cells/µL
  • IgE 95 IU/mL
  • FeNO 40 ppb
  • 2 severe exacerbations in the past year
    Compromised lung function: 65% FEV1 % predicted
  • Diagnosed with adult-onset asthma at age 28
    Lack of asthma control
  • Triple therapy: High-dose ICS/LABA + LAMA

THE ONLY BIOLOGIC INDICATED FOR OCS-DEPENDENT ASTHMA PATIENTS, REGARDLESS OF PHENOTYPE

OCS-DEPENDENT
ASTHMA PATIENT
  • EOS 140 cells/µL
  • IgE 405 IU/mL
  • 2 severe exacerbations in the past year
    Compromised lung function: 58% FEV1 % predicted
  • Diagnosed with adult-onset asthma at age 23
    Lack of asthma control
  • Daily OCS use
    Triple therapy: High-dose ICS/LABA + LTRA

Patient profiles are representative and are not actual DUPIXENT patients.


  • LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.



DUPIXENT MyWay®

See how eligible patients can access support for DUPIXENT

LEARN MORE

LEARN MORE ABOUT DUPIXENT

as add-on maintenance therapy
in moderate-to-severe asthma patients

REGISTER FOR UPDATES
    References:
  1. DUPIXENT Prescribing Information.
  2. Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.